{"name":"Avirmax Biopharma Inc","slug":"avirmax-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ABI-110 Medium Dose","genericName":"ABI-110 Medium Dose","slug":"abi-110-medium-dose","indication":"Other","status":"phase_1"},{"name":"ABI-110 High Dose","genericName":"ABI-110 High Dose","slug":"abi-110-high-dose","indication":"Other","status":"phase_1"},{"name":"ABI-110 Low Dose","genericName":"ABI-110 Low Dose","slug":"abi-110-low-dose","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ABI-110 Medium Dose","genericName":"ABI-110 Medium Dose","slug":"abi-110-medium-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABI-110 High Dose","genericName":"ABI-110 High Dose","slug":"abi-110-high-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABI-110 Low Dose","genericName":"ABI-110 Low Dose","slug":"abi-110-low-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNR3NmM1NMaWZUY3gyLWdNVldPTFRuRXBfT3dvSnowcXp3MUxqMGs0Um5KVV9RMEMwUEc5TmlMRFFodzhjQVY5aGZ2anNjMmg0WW15R2lUbkFKVUJDekdfMnpJODNIQlpabDl4QVBRaGpsOHd2aGtsN0ZRVC16dXN1N25ENmJBSU1RMnlNTzl3TTlBQUVmTmthNktERnhjeDN1dU44QVVsVzYwNWMzTVE?oc=5","date":"2025-04-30","type":"pipeline","source":"Ophthalmology Times","summary":"Companies announce presentations at upcoming 2025 ARVO Annual Meeting - Ophthalmology Times","headline":"Companies announce presentations at upcoming 2025 ARVO Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNMjZULWMwcE9hMGM3UFU2cXNTN3ctanRTSFNqY201QWQtZmx5Wjl0RTVWMkhXdXVwU24tdWJlSmgtaTFjb2lyRU1TRE1OS295N1VkMksteVN6OUNDM19LZ005TGZsR0NjUWtfcm5US21aVl91SlV5UmZfRHhuVWxsLWtLZnBFazFxdEN3VFBJUi1EX191MTdISzUydGFlUTkwQXc?oc=5","date":"2025-03-05","type":"trial","source":"Ophthalmology Times","summary":"Avirmax Biopharma prepares for IND-enabling study of ABI-201 - Ophthalmology Times","headline":"Avirmax Biopharma prepares for IND-enabling study of ABI-201","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQb2QyVEVKd1VPYXotRkw3alkzWTlRMThvcDlLcE56UjVQclZGTWlwOGtIZHFEWkk5SWN4Yk1XOVkzaFNST0VDVXVuNVRaRE1LdDFhMjRGZHB6eGJFLU1HVEI5MWxoOF9CUHZkZ05uNnhTUTNfQjFQU3ZteHZjVXBJV1VJbHV4T25nYTlYWHdQdGxMUFB2a2RKeGdqb2oxRExzQ0xQdjJ0YWVFNDNDb0lzdXlDbHpwWkJkbm1JWHhFbjhvemJuRVRLemp3RHJhRVZHSHVVWTNmNF9vNHlId0o4aEJXcXhJTTZFQ1NyNlN4cVdEUVpyak1VT2d0R0pBTUIySXBUQ3lSYjFYR0RwZ2UtTENB?oc=5","date":"2025-02-28","type":"pipeline","source":"PR Newswire","summary":"Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Degeneration - PR Newswire","headline":"Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Deg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNOEhQZU5SUDBVMVJTV01Lc3VSbFJvLVR4OVRQVXh2Tkc3cXNEaXd3cTJ4MEVfOEN2SFd3cm51Y0JBZ3NyMUVnSHo5V2tRbFNpZk5xMXMwcEZWTWY2QWJsYmdqSi14SmtVUXdfMk9vUG44a3hZUjE3eHdBNzZWM0JxZV9ROEgwRkJ5ZmR0VVZnTWFMUXVpdnZGTmN0dC1VRkdOX0FjUk44djd5b0JVVkFKWWtQdWNLcXVwTVlCc3pja2JuRzdYX3FQVmxiYkpreXh2UTZ1V2NZZmlReGdWanNXV3RSUzFNbjNNd0lLbFJFdHFRdVJraDk5QUMybEh1WDFBYjhvNk85ekI0STM4SWpYNnBiTWpKM3FkYnU3UllfS29id2NXZEttQmE1WTBEelE?oc=5","date":"2025-02-03","type":"trial","source":"PR Newswire","summary":"Avirmax Biopharma Announces Completion of the First Cohort of Patient Enrollment in Clinical Trial of ABI-110, a Gene Therapy for Wet AMD Including PCV - PR Newswire","headline":"Avirmax Biopharma Announces Completion of the First Cohort of Patient Enrollment in Clinical Trial of ABI-110, a Gene Th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxOanZQNWtVZE1MTlktRngwWndCWmZuaGdQLTNobFZQQjVHSGg0OUZtUTF3SG1xX3RRQzVqazR4TXV4Mi1OSzRJQ1NXRzBHM1dZTlB2Q2JTMXJ1WnFFY1ZwZnhmNWd5UkhHZ2FyZkxIOFY0Ujk5OEV2ZEo5MGtPaUVzVDByZC1yOURUMm1iVllaVG1fYWVxZld5SFJwSkdNNDRnNW94ZUM5ck02MmRiR1FUUjVER1Rzc1Z1LWhURGRTQ0pHTnY2ZXVjM3BWdzV6OFBhYW10MENuSkVhb1cxd29Qdnp0NkU1WUJqQWJIY29rX0lNeXZmOEJXZ1BBcGZwMFJMcjE4cEU1NkVrZEZKUXpJeTdzcE1BVDQ?oc=5","date":"2024-11-21","type":"trial","source":"PR Newswire","summary":"Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV - PR Newswire","headline":"Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQMVlEa0Y0T1RhS3ppaVBKeGM0VGNzRk9UMVkxQUZVYjh4amNrUl8wRklOdE5Hd0lnUnhidm9KVURqQ0drZzRhOUxGTDl0NUZ5b2swYmtwNTNuZDVDcHhKMVFwZVRCTG5xNE5pNHlWN2VITERZZkdzeW9ZaWUzN2JTcVNYc2ZndVB5WWpQWGY4Yk5OZ3pMdHV3VzhGbE5EZTNvYjZaZGtqNU9GMFd0NTR2LVloLVZBTGZ2MGJNNW5hNUVNMGtua2ZqdE43aWpWSFJqMVliTVhzZXJmbXFocENVZnV3?oc=5","date":"2024-07-17","type":"trial","source":"PR Newswire","summary":"Avirmax CMC Successfully Delivers First GMP Lot of AAV Vector Product for Clinical Trial Use - PR Newswire","headline":"Avirmax CMC Successfully Delivers First GMP Lot of AAV Vector Product for Clinical Trial Use","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPaS1rYzhjUEs2el95bndUeXJmeXA4WV92c1N4dkxSazVLMExFaTdlaFhDRVZqNVZlN0s0OXpmdlNJRzRQaUM3eGlCY1lIVlZ1Wm04cExGSk8yRThGa1U2WHZ2S1FzUlRDWFU1TTNmaDdvbk45Y1kwZk83UWxtYWlJRmlMSG1tSVY5WUpkY3NpOUpHX282VjdiWDNPT2JDM2QxZ2Z3VnBjZHhRVHozMkxBQnFnQ2Q3M0V1TFZBaGNJX0NoQ213N3YwSGZMcW9RUnkwSTBQaTJvcTBNUTJEbFFGU1l5VWdQdw?oc=5","date":"2024-05-30","type":"regulatory","source":"PR Newswire","summary":"Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV - PR Newswire","headline":"Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNZGZaNHpYRkRUY084cXpyajVVcnhyLVRxVG1jT2xCbm5sXzNvVm1NdUcycHZKeTY2alZqbEpUN2JfM1dwbEExdlR1LWptQldWRHM0RzJZbnY0VUlmYVh5aE9NckFCd0FSZGUzQ0FHQjFoZHFHanJ5S1J3UWpSeXJodi1KQUdRbTZROVFnYkZDRXFseS1BN3c?oc=5","date":"2024-04-16","type":"pipeline","source":"BioSpace","summary":"Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore - BioSpace","headline":"Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}